Moreover, whereas pretreatment with ERK and p38 inhibitors (U0126 and SB203580) reverse changes in periostin-promoted EMT markers in lung cancer cells, application of the JNK inhibitor (SP600125) has no such effect (Figure 3B and 3C).Pretreatment with ERK and p38 inhibitors inhibited scattering morphology, wound healing, migration and invasion potential of lung cancer cells (Figure 3D-3H, Supplementary Figure 2). The gene discussed is MAPK8; the disease is lung carcinoma.